Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma

Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical development.

The round was led by Yuanbio Venture Capital, with participation from a group of new and existing investors. According to Inno Medicine, proceeds will primarily support international multicenter trials of its core pipeline and accelerate the programs toward commercialization. (Innovmedicine)

What makes the financing particularly notable is where Inno Medicine now sits in its development cycle. The company is no longer simply trying to demonstrate that its delivery technology works. Its lead cardiovascular program, YN001, has entered a multinational Phase 2b trial, while its brain-tumor candidate YN003 recently secured both U.S. IND clearance and FDA Fast Track designation.

Both emerged from the same underlying technology: Inno Medicine’s proprietary Active Targeting Liposome, or ATL, delivery platform. (Innovmedicine)

ATL: Using Drug Delivery to Change Where a Medicine Goes

Founded in 2016, Inno Medicine has built its R&D strategy around actively targeted nanomedicine rather than conventional systemic drug delivery.

The basic idea behind ATL is straightforward but technically difficult: package therapeutic payloads inside engineered liposomal nanoparticles and guide those particles preferentially toward diseased tissue.

In theory, concentrating a drug at its intended target could increase local exposure while limiting unnecessary exposure elsewhere in the body. That could potentially improve efficacy, widen the therapeutic window and reduce systemic toxicity.

Inno Medicine is applying that principle to two very different biological problems—atherosclerotic plaque in cardiovascular disease and malignant tissue in the brain. (Innovmedicine)

The progress of YN001 and YN003 will therefore test something larger than the individual drugs. They will help determine whether ATL can become a repeatable delivery platform capable of generating medicines across multiple therapeutic areas.

YN001 Takes Direct Aim at Atherosclerotic Plaque

The most advanced program is YN001, which Inno Medicine describes as the world’s first actively targeted therapy designed to reverse atherosclerotic plaques.

Rather than relying solely on systemic lipid lowering, YN001 is designed to selectively accumulate within atherosclerotic lesions and act directly on the plaque.

The candidate combines two complementary effects: reducing inflammation within the lesion while promoting cholesterol efflux and reverse cholesterol transport, moving cholesterol out of plaque and back into circulation for subsequent clearance. Inno Medicine believes this could reduce plaque burden while simultaneously improving plaque stability. (Innovmedicine)

That is an ambitious objective.

Modern cardiovascular therapy has become extremely effective at reducing circulating LDL cholesterol, but residual cardiovascular risk remains substantial even among aggressively treated patients. A medicine capable of directly reducing existing coronary plaque could therefore address a different part of the disease process.

Inno Medicine is now putting that hypothesis to a much larger clinical test.

PURIFY-TIMI 81 Moves Into Phase 2b

YN001 is being evaluated in PURIFY-TIMI 81 (NCT07521007), a multinational, randomized, double-blind, placebo-controlled Phase 2b study in adults with coronary atherosclerosis.

The trial is expected to enroll approximately 456 participants receiving standard background therapy for cardiovascular risk-factor management. Patients receive intravenous YN001 or placebo, with the study designed to assess whether treatment can reduce coronary non-calcified plaque volume. (TrialRadar)

Recruitment began in 2026, and the latest trial record lists the study as recruiting. Inno Medicine says centers in China, Australia and the United States are being activated, with Canadian participation expected as the global study expands. (Innovmedicine)

The involvement of the TIMI Study Group is also noteworthy. The group has played a major role in many pivotal cardiovascular development programs, giving PURIFY-TIMI 81 an experienced international clinical-trial framework as Inno Medicine attempts to move YN001 toward registration. (TrialRadar)

If the study shows convincing plaque regression alongside an acceptable safety profile, YN001 could provide important clinical validation not only for the drug itself but for Inno Medicine’s targeted-delivery strategy.

YN003 Tackles an Entirely Different Delivery Problem

The company’s second major program demonstrates the potential breadth of ATL.

YN003 is an actively targeted nanomedicine being developed for adult glioma, including glioblastoma, one of the most aggressive and difficult-to-treat primary brain cancers.

Here, the delivery challenge is fundamentally different.

The blood-brain barrier protects the central nervous system by preventing many circulating molecules from reaching brain tissue—but that same protective mechanism makes drug development for brain tumors exceptionally difficult.

Inno Medicine designed YN003 to cross the blood-brain barrier and preferentially accumulate within glioma tissue, increasing drug concentration in the tumor while reducing exposure to healthy tissue elsewhere in the body. (Innovmedicine)

The company says the candidate goes beyond direct tumor-cell killing. YN003 can also induce immunogenic cell death, releasing tumor-associated signals that activate dendritic cells and T-cell-mediated adaptive immune responses.

That creates the possibility of combining direct cytotoxic activity with a secondary antitumor immune response. (Innovmedicine)

FDA Clears YN003 for U.S. Development

YN003 has already reached several important regulatory milestones in the United States.

The FDA cleared the drug’s Investigational New Drug application on July 13, 2026, allowing Inno Medicine to proceed with U.S. clinical development.

Days later, the agency granted Fast Track designation for YN003 in adult glioma, including glioblastoma. The designation is intended to facilitate development and regulatory review of therapies targeting serious diseases with significant unmet medical need. (Innovmedicine)

YN003 had previously received FDA Orphan Drug Designation in November 2023, giving the program another regulatory incentive as it advances in a relatively small but extremely high-need patient population. (Innovmedicine)

These designations do not establish that YN003 is effective, of course. That will require clinical evidence. But they provide Inno Medicine with a clearer U.S. regulatory pathway and opportunities for more frequent interaction with the FDA as development progresses.

Series D Arrives at a Critical Moment

The nearly RMB 800 million financing comes at an important transition point for Inno Medicine.

Early biotechnology companies can often advance a platform and initial clinical programs with relatively modest funding. Running multinational mid- and late-stage studies is a very different proposition. Clinical sites, manufacturing, regulatory work and global development infrastructure quickly become expensive.

Inno Medicine says the new Series D capital will primarily support international multicenter clinical development of its core programs, positioning the company to push both YN001 and YN003 further through the clinic. (Innovmedicine)

The financing also reflects a broader trend in China’s biotechnology sector.

Chinese drug developers are increasingly moving beyond conventional small molecules and antibodies into enabling technologies—ADCs, radiopharmaceuticals, cell therapies, RNA medicines and sophisticated drug-delivery systems—that can potentially generate multiple differentiated products from a single platform.

Inno Medicine belongs squarely in that group.

The company has spent years building ATL around the premise that where a drug goes can be just as important as what the drug is. YN001 and YN003 now provide two very different tests of that thesis: one targeting plaque inside coronary arteries and the other attempting to penetrate the blood-brain barrier and reach malignant brain tissue.

The next major readouts will determine whether the promise translates clinically. But with nearly RMB 800 million in new financing, a 456-patient international cardiovascular study underway and YN003 cleared for U.S. clinical development, Inno Medicine has moved into a much more consequential stage of its evolution.

If ATL can demonstrate meaningful targeting advantages in both cardiovascular disease and CNS oncology, the platform could ultimately become more valuable than either individual program.

References

Inno Medicine — Series D Financing Announcement
https://en.innovmedicine.com/news/details_25_178.html

Inno Medicine — FDA Fast Track Designation for YN003
https://en.innovmedicine.com/news/details_25_177.html

ClinicalTrials.gov — PURIFY-TIMI 81 (NCT07521007)
https://clinicaltrials.gov/study/NCT07521007

Inno Medicine — Active Targeting Liposome (ATL) Technology
https://en.innovmedicine.com/news/details_25_174.html